Abstract
Introduction: Calcium flux is the master second messenger that influences the proliferation–apoptosis balance. The ability of calcium flux alterations to reduce cell growth makes ion channels interesting targets for therapy. Among all, we focused on transient receptor potential vanilloid 1, a ligand-gated cation channel with selectivity for calcium. Its involvement in hematological malignancies is poorly investigated, especially in the field of chronic myeloid leukemia, a malignancy characterized by the accumulation of immature cells.
Methods: FACS analysis, Western blot analysis, gene silencing, and cell viability assay were performed to investigate the activation of transient receptor potential vanilloid 1, by N-oleoyl-dopamine, in chronic myeloid leukemia cell lines.
Results: We demonstrated that the triggering of transient receptor potential vanilloid 1 inhibits cell growth and promotes apoptosis of chronic myeloid leukemia cells. Its activation induced calcium influx, oxidative stress, ER stress, mitochondria dysfunction, and caspase activation. Interestingly, a synergistic effect exerted by N-oleoyl-dopamine and the standard drug imatinib was found.
Conclusion: Overall, our results support that transient receptor potential vanilloid 1 activation could be a promising strategy to enhance conventional therapy and improve the management of chronic myeloid leukemia.
1 Introduction
Intracellular calcium (Ca2+), one of the most important second messengers, is subjected to continuous fluctuations, essential in the control of cell proliferation, differentiation, migration, and death (; ; ; ). Interestingly, it is well recognized that the irregularity in Ca2+ channel expression and functions and the consequent associated alterations of the Ca2+ flux contribute significantly to the development of cancer. It is therefore not surprising that in recent years, cancer has also been classified as a “channelopathy” (). In this scenario, several studies described the essential role played by transient receptor potential (TRP) channels, the non-selective cation-permeable receptors localized in plasma membrane, endoplasmic reticulum, mitochondria, and lysosomes, in regulating cation concentrations and membrane voltage (). Furthermore, many scientific contributions described the involvement of TRP dysregulations in cancer growth, metastasis, and chemoresistance (). Among TRP channels, the opening of TRP vanilloid 1 (TRPV1), a ligand-gated cation channel activated by capsaicin (CPS), resiniferatoxin, temperatures over 43°C, acidic conditions (pH < 6), and endogenous cannabinoids, impacts the fine regulation of the proliferative signaling/cell death pathways by mainly modifying the Ca2+ influx (). TRPV1 activation was found to be involved in the induction of cell death in different cancer models including bladder cancer (), glioma (), human gastric cancer, and breast cancer (; ). Moreover, the triggering of TRPV1 facilitates the stimulation of pro-apoptotic and anti-proliferative effects in primary lymphoblasts obtained from both patients with T-acute lymphoblastic leukemia and the Jurkat cell line (). In this regard, the involvement of TRP channels in hematological malignancies is poorly investigated, especially in the field of myeloid leukemia. In this tumor type, it has only been demonstrated that the activation of TRPV5 and TRPV6 promotes a Ca2+-dependent cell cycle arrest (), and the inhibition of TRPM7 impairs cell proliferation and stimulates erythroid differentiation in K562 cells (). In addition, we recently showed that TRPV2 activation induced mitophagy associated with cell growth inhibition and stemness reduction in chronic myeloid leukemia (CML) cells ().
CML is a hematological malignancy that is characterized by the accumulation of immature cells as the consequence of the inadequate differentiation pathway of the hematopoietic progenitors. The evolution of this disease comprises three stages: chronic phase, accelerated phase, and blast crisis (). The present-day approved therapy is the administration of tyrosine kinase inhibitors (TKIs) in addition to allogeneic stem cell transplantation or interferon administration. However, the prolonged treatment with TKIs leads to the development of resistance and, for this reason, therapy interruption is required which affects the survival of patients (). Therefore, considering the implications of using TRPV1 modulators as potential therapeutic approaches represents a fascinating challenge and a new resource in the pharmacological field. To date, two dozen TRPV1 modulators are already used in clinical studies to evaluate their effects in inflammation and pain (). The historical agonists of the TRPV1 channels are CPS and resiniferatoxin, but in the last decades a new, more selective, and potent agonist, N-oleoyl-dopamine (OLDA), has attracted interest ().
Thus, the aim of this study is to investigate the activation of TRPV1 by OLDA in CML cells, focusing the attention on signaling pathways such as autophagy, endoplasmic reticulum (ER) stress, and apoptotic cell death. Furthermore, the co-administration of OLDA with the conventional drug imatinib was also investigated to elucidate the potential role of the combination of these two drugs in managing CML.
2 Materials and methods
2.1 Cell lines
Human chronic myeloid leukemia K562, KU812, and MOLM-6 cell lines were obtained from DSMZ-German Collection of Microorganisms and Cell Cultures GmbH (DSMZ, Braunschweig, Germany) and were maintained in RPMI-1640 medium (Euroclone Ltd., Devon, United Kingdom) supplemented with 10% heat-inactivated fetal calf serum (Euroclone), 2 mM L-glutamine, 100 IU/ml of penicillin, and 100 μg/ml of streptomycin.
The buffy coat, no longer used for transfusion, kindly provided by the Transfusion Center of Macerata Hospital after authorization of the hospital management (Direzione Medica Presidio Ospedaliero Unico AV3, Medical Director Dr. Carlo Di Falco), was only used in vitro to obtain an enrichment of normal myeloid cells using a RosetteSepTM HLA Myeloid Cell Enrichment Kit (STEMCELL Technologies, Cambridge, United Kingdom).
2.2 Chemicals and reagents
Capsazepine (CPZ), capsaicin (CPS), imatinib mesylate, ionomycin, propidium iodide (PI), and 2′,7′-dichlorofluorescin diacetate (DCFDA) were purchased from Sigma-Aldrich (Milan, Italy). The Fluo-3 AM calcium indicator and JC-1 were purchased from Thermo Fisher Scientific (Waltham, MA, United States). A784168 was purchased from Bio-Techne S.R.L (Milan, Italy). N-oleoyl-dopamine (OLDA) was purchased from Tocris (Bristol, United Kingdom). CPZ, CPS, and OLDA were dissolved in DMSO and were used as vehicle (maximum percentage 0.05, considered non-toxic) ().
Antibodies (Abs) were used according to manufacturer’s instructions: anti-phospho-histone γH2AX (Ser139) (γH2AX), anti-caspase 3, anti-binding immunoglobulin protein (BiP), anti-phospho-ubiquitin (pSer65), anti-microtubule-associated protein-1 light chain 3 (LC3), anti-activating transcription factor 4 (ATF4), anti-autophagy protein 12 (ATG5–ATG12), and anti-GAPDH were purchased from Cell Signaling Technology (1:1000, Danvers, MA, United States). Anti-transient receptor potential channel vanilloid 1 (TRPV1) was purchased from Invitrogen (1:1000, Waltham, Massachusetts, United States). Secondary Abs used were: HRP-conjugated anti-rabbit IgG (1:5000, Jackson ImmunoResearch Europe Ltd., Ely, United Kingdom); HRP-conjugated anti-mouse IgG (1:2000, Cell Signaling Technology); and PE-conjugated goat anti-rabbit Ab (1:40, BD Biosciences, Milan, Italy). The OxyBlot Protein Oxidation Detection Kit was purchased from Merck Life Science (Milan, Italy).
2.3 Cell viability assay
A density of 2 × 105 CML cells/mL was plated in 12-well plates. The next day, cells were exposed to different concentrations of OLDA (0.5–100 μM), CPS (10–300 μM), or the respective vehicle for 24 h. Then, cells were stained with trypan blue and counted using the TC20 automated cell counter according to the instrument instruction (Bio-Rad, Milan, Italy). This automated cell counter uses multifocal plane analysis to assess cell viability. Three replicates were carried out for each treatment. IC50 (half-maximal inhibitory concentration) values, shown as the mean ± standard deviation (SD), were calculated using GraphPad Prism® 9.1 (GraphPad Software, San Diego, CA, United States). In some experiments, cell counting was performed on siTRPV1 or siGLO CML cells treated with OLDA (IC50) or vehicle. OLDA was used in combination with imatinib mesylate for 24 h. Synergistic activity of OLDA–imatinib combination was determined by isobologram analysis and combination index (CI) methods (CompuSyn Software, ComboSyn, Inc.). The CI was used to express synergism (CI < 1), additivity (CI = 1), or antagonism (CI > 1).
2.4 Gene silencing and quantitative real-time PCR (qRT-PCR)
TRPV1 (siTRPV1) and siGLO non-targeting siRNA (used as the control), FlexiTube siRNA, were purchased from Qiagen (Milan, Italy). The day before transfection, CML cells were diluted at the density of 6 × 105 cells/mL in the culture medium. After 24 h, cells were collected, counted, and plated at the density of 4 × 105 cells/mL, and siTRPV1 or siGLO (50 nM) was added according to the HiPerFect Transfection Reagent protocol (Qiagen). Cells were then harvested at 48 h post transfection. Silencing efficiency was evaluated by qRT-PCR and Western blotting. No differences in TRPV1 expression and cell viability were observed in siGLO-transfected cells compared with siGLO-untransfected cells.
Total RNA was extracted using the RNeasy Mini Kit (Qiagen), and cDNA was synthesized using the iScript Advanced cDNA Synthesis Kit (Bio-Rad) according to manufacturers’ protocol. qRT-PCR was performed using QuantiTect Primer Assays for human TRPV1 (QT00046109) and GAPDH (QT00079247), as a reference gene (Qiagen), using the iQ5 Multicolor Real-Time PCR Detection System (Bio-Rad). The PCR parameters were in accordance with the primer datasheet. All samples were assayed in triplicate. Gene expression analysis was performed using iQ5 software.
2.5 Intracellular calcium influx [Ca2+]i
Intracellular Ca2+ influx was measured using Fluo-3 AM and FACS analysis. Briefly, 1.5 × 106 CML cells/mL were first washed in calcium- and magnesium-free PBS supplemented with 4.5 g/L of glucose and then incubated in calcium- and magnesium-free PBS/glucose medium supplemented with 7 μmol/L Fluo-3 AM for 30 min in the dark at 37°C and 5% CO2. After washing, cells were resuspended in calcium- and magnesium-free PBS/glucose medium containing 2 mmol/L Ca2+ and were stimulated with OLDA (IC50 dose) or with vehicle up to 3 min. In some experiments, CML cells, loaded as described previously, were treated with OLDA in combination with CPZ (10 µM) or A784168 (1 µM). Ionomycin (5 μg/ml) treatment was used as a positive control for measuring calcium influx. Fluo-3 AM fluorescence was measured using the BD Accuri C6 Plus flow cytometer and its software (Beckton Dickinson, San Jose, CA, United States).
2.6 Western blot analysis
Lysate from CML cells, treated or not treated with OLDA at the IC50 dose, was extracted using lysis buffer (10 mM Tris; 100 mM NaCl; 1 mM EDTA; 1 mM EGTA; 1 mM NaF; 20 mM Na4P2O7; 2 mM Na3VO4; 1% Triton X-100; 10% glycerol; 0.1% SDS; 0.5% deoxycholate; and 1 mM PMSF) containing protease-inhibitor cocktail (Euroclone). Proteins were separated on 8%–14% SDS-polyacrylamide gels and transferred using Bio-Rad systems. Non-specific binding sites were blocked with 5% low-fat dry milk or 5% BSA in PBS containing 0.1% Tween 20 for 1 h at room temperature. Membranes were incubated overnight at 4°C with anti-LC3, anti-ATG12, anti-ATF4, anti-BiP, anti-γH2AX, anti-caspase 3, anti-phospho-ubiquitin (pSer65), or anti-GAPDH Abs, followed by corresponding HRP-conjugated secondary Abs. In some experiments, Western blot analysis was performed on siTRPV1 and siGLO (control) CML cells treated with OLDA or vehicle to assess BiP expression levels. Moreover, lysates from CML cells were treated with OLDA at the IC50 dose and imatinib mesylate (0.5 µM), either alone or in combination, for 24 h were incubated with anti-γH2AX and anti-caspase 3.
In addition, the protein oxidation products were identified in CML cells, which were treated as described previously, by scanning carbonyl groups using the OxyBlotTM Protein Oxidation Detection Kit according to the manufacturer’s instructions. In brief, dinitrophenylhydrazine was added to the crude total proteins (20 μg) to derive the carbonyl groups from the protein side chains. Carbonylated proteins were resolved by SDS-polyacrylamide gel electrophoresis, and Western blot analysis was performed using the provided anti-DNP antibody (1:150).
The detection was performed using LiteAblot PLUS kit, ChemiDoc, and Quantity One software (Bio-Rad). GAPDH was used as the loading control. SHARPMASS VI–VII (Euroclone) and SeeBlue Plus2 (Invitrogen) were used as pre-stained protein markers.
2.7 Cell death, reactive oxygen species (ROS) production, and mitochondrial transmembrane potential (∆Ψm) analysis
CML cells, treated with OLDA or vehicle at the IC50 dose for 24 h, were incubated with 2 μg/mL PI for 30 min at 37°C. After washing, the fluorescence intensity was analyzed using BD Accuri C6 Plus software. The fluorescent probe DCFDA was used to assess oxidative stress levels in siTRPV1 and siGLO CML cells after treatment with OLDA (IC50). Cells were incubated with 20 μM DCFDA for 20 min prior to the harvest time point. After washing, the fluorescence was assayed using the BD Accuri C6 Plus flow cytometer and its software. ∆Ψm was evaluated by JC-1 staining according to the manufacturer’s protocol in CML cells, treated with OLDA or vehicle at the IC50 dose for 24 h. Samples were then analyzed using the BD Accuri C6 Plus flow cytometer and its software.
2.8 Bioinformatics analysis
BloodSpot, Stemformatics, and GEO are open-access downloaded bio-database that provide visualization and are analyzing tools for large-scale genomics datasets. In particular, BloodSpot (https://www.bloodspot.eu) provides gene expression profiles of healthy and malignant hematopoiesis in humans or mice, encompassing a total of more than 5,000 samples analyzed using a oligonucleotide microarray chip and by RNA-seq assay (). Stemformatics (https://www.stemformatics.org/) is an established gene expression data portal containing over 420 public gene expression datasets derived from microarray, RNA sequencing, and single-cell profiling technologies. Its major focus is on pluripotency, tissue stem cells, and staged differentiation (). The Gene Expression Omnibus database (http://www.ncbi.nlm.nih.gov/geo) is an open functional genomics database of a high-throughput resource ().
Analysis of data from database IDs 6326 and 6610 from Stemformatics (accessed on 4 November 2022) and GSE24759 and GSE13159 from GEO was performed in silico (accessed on 13 December 2022). The hierarchical tree was analyzed in the BloodSpot online database (accessed on 13 December 2022).
2.9 Statistical analysis
The statistical significance was determined by Student’s t-test and by ANOVA with Dunnett’s post hoc test. No statistically significant differences were found between siGLO-untransfected and -transfected CML cells, treated or not treated with a vehicle at different times (data not shown). Given the absence of differences, for simplicity, as the control, in time-course analysis, cells treated with vehicle for 24 h were shown.
3 Results
3.1 The activation of TRPV1 affects CML cell viability
We recently demonstrated the expression of TRPV1 on K562, KU812, and MOLM-6 CML cell lines, common myeloid progenitors, normal myeloid cell enrichment, and PBMCs, respectively (). To enhance our analysis of TRPV1 expression, we have also performed in silico analyses with datasets 6326/6610 from the Stemformatics database and GSE13159 from the GEO repository, demonstrating its expression in all types of leukemia cells (Supplementary Figure S1A). Interestingly, TRPV1 expression in common myeloid CML progenitors is modulated during the different phases of the disease with higher levels during the chronic phase (Supplementary Figure S1B).
It is well known that TRPV1 is the receptor for CPS; however, several sources of evidence demonstrated that the endogenous compound OLDA is a more potent and selective TRPV1 agonist (; ). Thus, CML cells were treated with CPS (10–300 μM) and OLDA (0.5–100 μM) for 24 h and analyzed by cell viability assay. OLDA induced a stronger decrease in cell viability than CPS, as shown by the IC50 values: 14.1 μM vs 140.1 μM in K562, 1.4 μM vs 129.8 μM in KU812, and 8.4 μM vs 173.9 μM in MOLM-6 (Figures 1A, B). For this reason, we selected OLDA as the TRPV1 agonist, and doses in the IC50 range (10 µM for K562 and MOLM-6; 1 µM for KU812) are considered for the subsequent experiments.
FIGURE 1
To assess the involvement of TRPV1, cell viability assay was evaluated in CML cells silenced for TRPV1 expression (siTRPV1) (Supplementary Figures S2A, B). TRPV1 silencing significantly reduced the OLDA effects compared to siGLO control cells, confirming that OLDA decreases cell viability by activating this channel (Figure 1C). We also assessed cell viability in normal myeloid cells, enriched from the blood of healthy donors, treated or not treated with OLDA at 1 µM and 10 µM (Supplementary Figure S3A). Results showed that in normal mature myeloid cells, OLDA is much less effective at reducing growth. This result is in line with our in silico analysis, in which the downregulation of TRPV1 expression occurs along the differentiation process (Supplementary Figure S3B).
3.2 The triggering of TRPV1 by OLDA induces oxidative stress in CML cells
The opening of the TRPV1 ligand-gated ion channel promotes transmembrane Ca2+ entry, which affects the fine balance between death and survival signaling pathways (). To assess the signaling pathway induced by OLDA, we first performed calcium mobilization assay for up to 3 min (data not shown). The increase in [Ca2+]i was found in CML cells treated with OLDA for 1 min after the stimulation compared to the vehicle (Figure 2A). This effect was inhibited by both the TRPV1 antagonists CPZ and A784168, validating the TRPV1 involvement in OLDA-induced effects (Figure 2B). Moreover, the [Ca2+]i overload was associated with a clear rise in ROS production induced by OLDA in a TRPV1-dependent manner as shown by the evident increase in DCFDA fluorescence in siGLO but not in siTRPV1 CML cells (Figure 2C; Supplementary Figure S4A). Mitochondria dysfunction is often the consequence of [Ca2+]i influx and ROS accumulation (). Thus, by performing JC-1 staining and FACS analysis, we showed that the treatment of CML cells with OLDA for 24 h induces a marked reduction in JC-1 red fluorescence, demonstrating mitochondrial depolarization (Figure 2D; Supplementary Figure S4B). Given that the interplay between [Ca2+]i and ROS, leading to mitochondrial impairment, is responsible for changes in macromolecules with consequent alterations of the cellular redox state (), Western blot analysis was performed to better elucidate the oxidation levels. Our results showed that OLDA treatment induces a robust enhancement in the oxidation of total proteins in all CML cell lines (Figure 2E). In addition, we also found that phospho-ubiquitin (Ser65) levels, correlated with injured mitochondria (), are strongly enhanced in OLDA-treated CML cells (Figure 2F), supporting that OLDA, by triggering TRPV1, induces oxidative stress and mitochondrial dysfunction.
FIGURE 2
3.3 OLDA treatment, via TRPV1, induces ER stress but not autophagy in CML cells
Autophagy, activated in response to several conditions including oxidative stress and mitochondrial alteration, is an essential pathway aimed at eliminating unwanted intracellular elements, such as unfolded oxidized proteins or damaged organelles, to promote cell survival (). To assess the induction of autophagy by OLDA treatment, we first analyzed the ATG12–ATG5 complex essential for autophagosome formation (). We found that in OLDA-treated CML cells, no increase in the expression levels of ATG12–ATG5 complex was evident, supporting that the execution of autophagy is not stimulated (Figure 3A). In addition, the conversion of the soluble form of LC3-I to the lipidated and autophagosome-associated form (LC3-II) was investigated. We found that OLDA treatment was not able to increase the expression of LC3-II in all CML cell lines (Figure 3B). To further strengthen our data, we also investigated the expression of ATF4, a transcription factor involved in stress-induced autophagy gene expression (). We showed that the treatment with OLDA was not able to upregulate the expression of ATF4 compared to vehicle-treated CML cells, highlighting once again that autophagy is not activated (Figure 3C).
FIGURE 3
These results prompted us to investigate endoplasmic reticulum stress, found to be stimulated under cellular stress conditions, which is characterized by the accumulation of misfolded proteins detected by the unfolded protein response (UPR). BiP, a chaperone protein abundant in ER, is considered the master stress sensor involved in UPR activation (). Therefore, to investigate the ER stress induced by OLDA via TRPV1, CML cells silenced for TRPV1 expression were treated with OLDA for 24 h. We found that the treatment with OLDA induces a strong upregulation of BiP expression levels in siGLO CML cells, used as the control, compared to siTRPV1 CML cells, indicating that ER stress is activated in a TRPV1-dependent manner (Figure 3D).
3.4 The ER stress induced by OLDA treatment leads to apoptotic cell death
Our next step was to investigate cell death in CML cells treated with the TRPV1 agonist OLDA, given that the UPR pathway may play a dual role in either providing survival benefits or triggering cell death (). The cytofluorimetric analysis showed that OLDA enhances the percentage of PI fluorescent cells, indicating the activation of cell death (Figures 4A, B), and, moreover, upregulates the expression of the Ser139-phosphorylated variant of histone 2A (γH2AX), supporting the presence of DNA double-strand breaks (Figure 4C). Finally, to assess the type of cell death, the analysis of caspase-3 cleavage was performed. The presence of cleaved caspase-3 fragments in OLDA-treated CML cells was found, demonstrating that the oxidative stress induced via TRPV1 by OLDA promotes apoptotic cell death in CML cells (Figure 4D).
FIGURE 4
3.5 OLDA synergizes with imatinib in reducing cell viability of CML cells
Presently, the common therapeutic strategy for the treatment of CML is based on TKIs such as imatinib. Therefore, as new strategies and new drug targets are always embraced to increase treatment possibilities, we used a computational approach to analyze the experimental data in order to elucidate the nature of the interaction between OLDA and imatinib. Cells were exposed to different doses of OLDA and imatinib for 24 h, and then the cell viability test was performed. Isobologram analysis demonstrated that several combinations of the two drugs provoke increased levels of cytotoxicity, when compared to single treatments (Figure 5A). In particular, the CI values obtained by combining OLDA at the IC50 dose with all the three doses of imatinib are < 1, indicating synergistic effects (Figure 5B). To support these data, we also performed Western blot analysis to assess DNA damage and apoptosis on CML cells treated with the combination of OLDA (IC50) and imatinib (0.5 µM). Our data demonstrated that the co-administration of both drugs is more effective in inducing upregulation of γH2AX and increasing caspase-3 fragment levels than the single treatment (Figures 5C, D), confirming the synergistic effects.
FIGURE 5
4 Discussion
As a result of an imbalance between proliferation and apoptosis with a marked preference for cell growth, cancer is characterized by a decrease in apoptosis, leaving malignant cells resistant to death (). However, apoptosis presents itself as a double-edged sword. In fact, it can be the problem and also provide a potential solution, since drugs aimed at activating and/or increasing apoptotic pathways are indeed coveted therapeutic options, especially in the field of leukemia (; ). In this scenario, Ca2+ influx is the master second messenger that influences the proliferation–apoptosis balance: low intracellular levels are required for cell growth stimulation, while its overload is strongly responsible for apoptosis induction (). Given that many anti-cancer drugs induce reduction in cell growth by disturbing [Ca2+]i, ion channels are interesting targets for therapy. In this regard, TRPV1, a ligand-gated cation channel also known as the CPS receptor with selectivity for Ca2+ over Na+, in addition to regulating nociception, metabolism, and thermoregulation, is involved in the modulation of the proliferation–apoptosis equilibrium, exactly because it modifies [Ca2+]i. It is expressed in neuronal and non-neuronal healthy cells as well as in many different cancer cells including acute T-cell leukemia (). Our previous work () demonstrated that TRPV1 was expressed at the molecular and protein levels in several CML cell lines. Furthermore, this study strengthened the evidence of expression of TRPV1 in all leukemia types, emphasizing its modulation during the progression of the disease with higher levels of leukemic common progenitors during the chronic phase where additional epigenetic changes contribute to blastic transformation and TKI resistance. In fact, patients with chronic-stage CML have many CD34+ leukemia cells with innate resistance to imatinib at the time of diagnosis (; ).
It is well known that TRPV1 activation in cancer cells such as urothelial, endometrial, and colorectal cancer cells, by strongly enhancing [Ca2+]i, promotes mitochondrial depolarization and ROS overproduction that leads to apoptotic cell death (; ; ). In agreement with these findings, we demonstrated that the triggering of TRPV1, by its agonist OLDA, induces increase in Ca2+ influx and ROS production with consequent mitochondrial dysfunction. Interestingly, the induction of mitochondrial impairment represents a promising approach given that the increased number of mitochondria and exaggerated mitochondrial activity were recognized in leukemia cells compared with normal hematopoietic stem cells (; ). Our data also showed that the increase in ROS, associated with the induction of oxidative stress and subsequent accumulation of oxidized proteins, does not promote survival autophagy but stimulates, in a TRPV1-dependent manner, ER stress followed by apoptosis. The autophagy machinery is activated during cellular stresses to digest damaged organelles, unwanted proteins, and intracellular materials. Thus, given that it is indispensable to maintain cellular homeostasis, several reports highlight its anti-tumoral action in CML by controlling ROS and DNA damage (; ). It has been demonstrated that CD34+ leukemia stem cells display a high level of autophagic flux, and, more importantly, TKI treatment, as the flip side, stimulates autophagy responsible for leukemia stem cell survival and establishment of drug resistance (). In fact, the targeting of autophagy with inhibitors in combination with conventional therapy has been suggested in the CML treatment, also to counteract the BCR-ABL-independent mechanism of resistance (). Thus, our results indicate that the induction of apoptosis, by the triggering of TRPV1, without stimulation of autophagic signals, could represent a good opportunity to contrast the survival signals induced by the same TKI therapy.
To date, much effort has been made to understand the role of ROS in CML pathogenesis. It is clear that leukemia progenitor cells are characterized by higher levels of ROS than normal hematopoietic cells. BCR-ABL1 oncoprotein is involved in the production of ROS that are then responsible for promoting genomic instability, a sort of “auto-mutagenesis” process that leads to malignancy (; ). In addition, it has surprisingly been found that TKI treatment during time favors the control of the redox cell state by activating the repair enzyme human MutT homolog 1 which removes the oxidatively damaged cellular nucleotide pool and repairs the DNA breaks, leading to a strong reduction in therapy efficacy itself and chemoresistance (). On the other hand, the drug-induced oxidative stress exaggeration in leukemic cells could intensify the genotoxic effects of conventional therapy, facilitating the activation of programmed cell death (). In fact, recent findings showed that the stimulation of oxidative stress in CML, using compounds such as tyrosol derivatives, verbascoside, and zerumbone, promotes mitochondrial membrane potential dissipation, caspase activation, and apoptosis (; ; ). Therefore, the strategy of deliberately increasing ROS to cytotoxic levels for leukemia cells seems to be very appealing, and our data are in agreement. The oxidative stress is often followed by the accumulation of unwanted proteins and ER stress, which triggers UPR to restore the homeostatic state, when the condition is toxic for the cell, and promote cell death (). Accordingly, our data consistently demonstrate that ER stress is activated by TRPV1, leading to apoptotic cell death. In this regard, ER stress-induced apoptosis of leukemia cells was also demonstrated (). Therefore, our results, by determining that the TRPV1-induced signaling cascade is responsible for increased ROS, ER stress, DNA damage, and programmed cell death, are in line with these findings. Moreover, we described a synergistic effect induced by combining the TRPV1 activator OLDA with imatinib in stimulating both DNA breaks and apoptosis in CML. This highlights the possibility to use TRPV1 triggering to counteract negative side of the TKI therapy itself and limit the development of resistance.
However, even if the signaling pathways induced by the TRPV1 activation were elucidated in three different CML cell lines, our study is based on an in vitro model. Thus, to bridge the gaps, our future direction is to confirm our results by using both blood collected from CML patients stratified according to TKI resistance and mouse models of CML. In recent years, several in vivo models of CML have been established, by using chimeric mouse strains as well as different immunocompromised strains (), to study the molecular pathogenesis of the disease and approach new therapeutic strategies. Thus, transgenic, conditioned, and/or xenograft mice CML models can be used to validate the effects of TRPV1 activation triggered by OLDA.
Interesting and innovative oncologic approaches based on TRPV1 activation have been developed in anti-cancer research, such as photothermal stimulation, development of specific nano-agonists, gold nanorod-assisted near-infrared irradiation-activated tool, and many synthetic as well as natural-origin activators. The aim of these studies is to exploit the opening of the TRPV1 channel to increase the cytoplasmic Ca2+ flux leading to apoptosis (). Overall, our findings underline the importance to trigger TRPV1 as an important avenue in CML management.
Statements
Data availability statement
The raw data supporting the conclusion of this article will be made available by the authors, without undue reservation.
Author contributions
Study concept and design: CoA, FM, and MBM. Acquisition of data: CoA, FM, and MBM. Analysis and interpretation of data: CoA, FM, and MBM. Critical revision and methodology supervision: MN, LZ, CrA, and CP. Drafting and editing of the manuscript: CoA, FM, MBM, and GS. All authors contributed to the article and approved the submitted version.
Funding
This research was supported by PRIN 2017 (prot. 2017FS5SHL).
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmolb.2023.1129202/full#supplementary-material
References
1
Abdelkafi-KoubaaZ.AissaI.ben JannetH.Srairi-AbidN.MarrakchiN.MenifS. (2022). Tyrosol derivatives, bearing 3,5-disubstituted isoxazole and 1,4-disubstituted triazole, as potential antileukemia agents by promoting apoptosis. Molecules27, 5086. 10.3390/molecules27165086
2
Akgun-CagliyanG.Cort-DonmezA.Kilic-ToprakE.AltintasF. (2022). Verbascoside potentiates the effect of tyrosine kinase inhibitors on the induction of apoptosis and oxidative stress via the Abl-mediated MAPK signalling pathway in chronic myeloid leukaemia. Exp. Ther. Med.24, 514. 10.3892/etm.2022.11441
3
AmantiniC.BallariniP.CaprodossiS.NabissiM.MorelliM. B.LucciariniR.et al (2009). Triggering of transient receptor potential vanilloid type 1 (TRPV1) by capsaicin induces Fas/CD95-mediated apoptosis of urothelial cancer cells in an ATM-dependent manner. Carcinogenesis30, 1320–1329. 10.1093/carcin/bgp138
4
AmantiniC.MoscaM.NabissiM.LucciariniR.CaprodossiS.ArcellaA.et al (2007). Capsaicin-induced apoptosis of glioma cells is mediated by TRPV1 vanilloid receptor and requires p38 MAPK activation. J. Neurochem.102, 977–990. 10.1111/j.1471-4159.2007.04582.x
5
ApperleyJ. F. (2015). Chronic myeloid leukaemia. Lancet385, 1447–1459. 10.1016/S0140-6736(13)62120-0
6
BaggerF. O.SasivarevicD.SohiS. H.LaursenL. G.PundhirS.SønderbyC. K.et al (2016). BloodSpot: A database of gene expression profiles and transcriptional programs for healthy and malignant haematopoiesis. Nucleic Acids Res.44, D917–D924. 10.1093/nar/gkv1101
7
BaqueroP.DawsonA.HelgasonG. V. (2019). Autophagy and mitochondrial metabolism: Insights into their role and therapeutic potential in chronic myeloid leukaemia. FEBS J.286, 1271–1283. 10.1111/febs.14659
8
BarbatoA.ScanduraG.PuglisiF.CambriaD.la SpinaE.PalumboG. A.et al (2020). Mitochondrial bioenergetics at the onset of drug resistance in hematological malignancies: An overview. Front. Oncol.10, 604143. 10.3389/fonc.2020.604143
9
BarrettT.SuzekT. O.TroupD. B.WilhiteS. E.NgauW. C.LedouxP.et al (2004). NCBI GEO: Mining millions of expression profiles--database and tools. Nucleic Acids Res.33, D562–D566. 10.1093/nar/gki022
10
B’chirW.MaurinA.-C.CarraroV.AverousJ.JousseC.MuranishiY.et al (2013). The eIF2α/ATF4 pathway is essential for stress-induced autophagy gene expression. Nucleic Acids Res.41, 7683–7699. 10.1093/nar/gkt563
11
BellodiC.LidonniciM. R.HamiltonA.HelgasonG. V.SolieraA. R.RonchettiM.et al (2009). Targeting autophagy potentiates tyrosine kinase inhibitor–induced cell death in Philadelphia chromosome–positive cells, including primary CML stem cells. J. Clin. Investigation119, 1109–1123. 10.1172/JCI35660
12
BootmanM. D.ChehabT.RietdorfK.ParysJ. B. (2018). The regulation of autophagy by calcium signals: Do we have a consensus?Cell Calcium70, 32–46. 10.1016/J.CECA.2017.08.005
13
BrookesP. S.YoonY.RobothamJ. L.AndersM. W.SheuS.-S. (2004). Calcium, ATP, and ROS: A mitochondrial love-hate triangle. Am. J. Physiology-Cell Physiology287, C817–C833. 10.1152/ajpcell.00139.2004
14
BulutI.LeeA.CevatemreB.RuzicD.BelleR.KawamuraA.et al (2022). Dual LSD1 and HDAC6 inhibition induces doxorubicin sensitivity in acute myeloid leukemia cells. Cancers (Basel)14, 6014. 10.3390/cancers14236014
15
ChoiJ.PachecoC. M.MosbergenR.KornO.ChenT.NagpalI.et al (2019). Stemformatics: Visualize and download curated stem cell data. Nucleic Acids Res.47, D841–D846. 10.1093/nar/gky1064
16
ChuC. J.HuangS. M.de PetrocellisL.BisognoT.EwingS. A.MillerJ. D.et al (2003). N-oleoyldopamine, a novel endogenous capsaicin-like lipid that produces hyperalgesia. J. Biol. Chem.278, 13633–13639. 10.1074/jbc.M211231200
17
CuiC.MerrittR.FuL.PanZ. (2017). Targeting calcium signaling in cancer therapy. Acta Pharm. Sin. B7, 3–17. 10.1016/j.apsb.2016.11.001
18
de Abreu CostaL.Henrique Fernandes OttoniM.dos SantosM.MeirelesA.Gomes de AlmeidaV.de Fátima PereiraW.et al (2017). Dimethyl sulfoxide (DMSO) decreases cell proliferation and TNF-α, IFN-γ, and IL-2 cytokines production in cultures of peripheral blood lymphocytes. Molecules22, 1789. 10.3390/molecules22111789
19
FenoS.ButeraG.Vecellio ReaneD.RizzutoR.RaffaelloA. (2019). Crosstalk between calcium and ROS in pathophysiological conditions. Oxid. Med. Cell Longev.2019, 9324018–18. 10.1155/2019/9324018
20
FonsecaB. M.Correia-da-SilvaG.TeixeiraN. A. (2018). Cannabinoid-induced cell death in endometrial cancer cells: Involvement of TRPV1 receptors in apoptosis. J. Physiol. Biochem.74, 261–272. 10.1007/s13105-018-0611-7
21
García RuizO.Sánchez-MaldonadoJ. M.López-NevotM. Á.GarcíaP.MacaudaA.Hernández-MohedoF.et al (2022). Autophagy in hematological malignancies. Cancers (Basel)14, 5072. 10.3390/cancers14205072
22
GeesM.ColsoulB.NiliusB. (2010). The role of transient receptor potential cation channels in Ca2+ signaling. Cold Spring Harb. Perspect. Biol.2, a003962. 10.1101/cshperspect.a003962
23
GiorgiC.DaneseA.MissiroliS.PatergnaniS.PintonP. (2018). Calcium dynamics as a machine for decoding signals. Trends Cell Biol.28, 258–273. 10.1016/j.tcb.2018.01.002
24
GłowackiS.SynowiecE.SzwedM.TomaM.SkorskiT.ŚliwińskiT. (2021). Relationship between oxidative stress and imatinib resistance in model chronic myeloid leukemia cells. Biomolecules11, 610. 10.3390/biom11040610
25
HeiseN.PalmeD.MisovicM.KokaS.RudnerJ.LangF.et al (2010). Non-selective cation channel-mediated Ca2+-entry and activation of Ca2+/calmodulin-dependent kinase II contribute to G2/M cell cycle arrest and survival of irradiated leukemia cells. Cell. Physiology Biochem.26, 597–608. 10.1159/000322327
26
HepowitN. L.KolbeC.ZelleS. R.LatzE.MacGurnJ. A. (2022). Regulation of ubiquitin and ubiquitin‐like modifiers by phosphorylation. FEBS J.289, 4797–4810. 10.1111/febs.16101
27
HouN.HeX.YangY.FuJ.ZhangW.GuoZ.et al (2019). TRPV1 induced apoptosis of colorectal cancer cells by activating calcineurin-NFAT2-p53 signaling pathway. Biomed. Res. Int.2019, 6712536–6712538. 10.1155/2019/6712536
28
KharazihaP.PanaretakisT. (2017). Dynamics of atg5–atg12–Atg16L1 aggregation and deaggregation. Methods Enzymol.587, 247–255. 10.1016/bs.mie.2016.09.059
29
KoppM. C.LarburuN.DurairajV.AdamsC. J.AliM. M. U. (2019). UPR proteins IRE1 and PERK switch BiP from chaperone to ER stress sensor. Nat. Struct. Mol. Biol.26, 1053–1062. 10.1038/s41594-019-0324-9
30
LeeY.OnishiY.McPhersonL.KietrysA. M.HebenbrockM.JunY. W.et al (2022). Enhancing repair of oxidative DNA damage with small-molecule activators of MTH1. ACS Chem. Biol.17, 2074–2087. 10.1021/acschembio.2c00038
31
LiL.ChenC.ChiangC.XiaoT.ChenY.ZhaoY.et al (2021). The impact of TRPV1 on cancer pathogenesis and therapy: A systematic review. Int. J. Biol. Sci.17, 2034–2049. 10.7150/ijbs.59918
32
LitanA.LanghansS. A. (2015). Cancer as a channelopathy: Ion channels and pumps in tumor development and progression. Front. Cell Neurosci.9, 86–11. 10.3389/fncel.2015.00086
33
LiuL.SunX.GuoY.GeK. (2022). Evodiamine induces ROS-Dependent cytotoxicity in human gastric cancer cells via TRPV1/Ca2+ pathway. Chem. Biol. Interact.351, 109756. 10.1016/j.cbi.2021.109756
34
MaggiF.MorelliM. B.TomassoniD.MarinelliO.AguzziC.ZeppaL.et al (2022). The effects of cannabidiol via TRPV2 channel in chronic myeloid leukemia cells and its combination with imatinib. Cancer Sci.113, 1235–1249. 10.1111/cas.15257
35
MitchellR.HopcroftL. E. M.BaqueroP.AllanE. K.HewitK.JamesD.et al (2018). Targeting BCR-ABL-independent TKI resistance in chronic myeloid leukemia by mTOR and autophagy inhibition. JNCI J. Natl. Cancer Inst.110, 467–478. 10.1093/jnci/djx236
36
MlynarczykC.FåhraeusR. (2014). Endoplasmic reticulum stress sensitizes cells to DNA damage-induced apoptosis through p53-dependent suppression of p21CDKN1A. Nat. Commun.5, 5067. 10.1038/ncomms6067
37
OsmanA. E. G.DeiningerM. W. (2021). Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions. Blood Rev.49, 100825. 10.1016/j.blre.2021.100825
38
Pascu VînturiŞE. G.GămanA. M. (2020). Involvement of oxidative stress in resistance to tyrosine-kinase inhibitors therapy in chronic myeloid leukemia. Curr. Health Sci. J.46, 420–432. 10.12865/CHSJ.46.04.14
39
PeczeL.JósvayK.BlumW.PetrovicsG.VizlerC.OláhZ.et al (2016). Activation of endogenous TRPV1 fails to induce overstimulation-based cytotoxicity in breast and prostate cancer cells but not in pain-sensing neurons. Biochimica Biophysica Acta (BBA) - Mol. Cell Res.1863, 2054–2064. 10.1016/j.bbamcr.2016.05.007
40
PengZ. G.LiuD. C.YaoY. B.FengX. L.HuangX.TangY. L.et al (2016). Paclitaxel induces apoptosis in leukemia cells through a JNK activation-dependent pathway. Genet. Mol. Res.15, 15013904. 10.4238/gmr.15013904
41
PerrottiD.JamiesonC.GoldmanJ.SkorskiT. (2010). Chronic myeloid leukemia: Mechanisms of blastic transformation. J. Clin. Investigation120, 2254–2264. 10.1172/JCI41246
42
PunzoF.ManzoI.TortoraC.PotaE.D’AngeloV.BelliniG.et al (2018). Effects of CB2 and TRPV1 receptors’ stimulation in pediatric acute T-lymphoblastic leukemia. Oncotarget9, 21244–21258. 10.18632/oncotarget.25052
43
RajanI.JayasreeP. R.KumarP. R. M. (2015). Zerumbone induces mitochondria-mediated apoptosis via increased calcium, generation of reactive oxygen species and upregulation of soluble histone H2AX in K562 chronic myelogenous leukemia cells. Tumor Biol.36, 8479–8489. 10.1007/s13277-015-3583-z
44
SeebohmG.SchreiberJ. A. (2021). Beyond hot and spicy: TRPV channels and their pharmacological modulation. Cell Physiol. Biochem.55, 108–130. 10.33594/000000358
45
ShapovalovG.Lehen’kyiV.SkrymaR.PrevarskayaN. (2011). TRP channels in cell survival and cell death in normal and transformed cells. Cell Calcium50, 295–302. 10.1016/j.ceca.2011.05.006
46
ShapovalovG.RitaineA.SkrymaR.PrevarskayaN. (2016). Role of TRP ion channels in cancer and tumorigenesis. Semin. Immunopathol.38, 357–369. 10.1007/s00281-015-0525-1
47
SontakkeP.JaquesJ.VellengaE.SchuringaJ. J. (2016). Modeling of chronic myeloid leukemia: An overview of in vivo murine and human xenograft models. Stem Cells Int.2016, 1625015–1625112. 10.1155/2016/1625015
48
SriskanthadevanS.JeyarajuD. v.ChungT. E.PrabhaS.XuW.SkrticM.et al (2015). AML cells have low spare reserve capacity in their respiratory chain that renders them susceptible to oxidative metabolic stress. Blood125, 2120–2130. 10.1182/blood-2014-08-594408
49
StornioloA.RacitiM.CucinaA.BizzarriM.di RenzoL. (2015). Quercetin affects hsp70/IRE1 α mediated protection from death induced by endoplasmic reticulum stress. Oxid. Med. Cell Longev.2015, 645157–645211. 10.1155/2015/645157
50
TakahashiK.UmebayashiC.NumataT.HondaA.IchikawaJ.HuY.et al (2018). TRPM7-mediated spontaneous Ca2+ entry regulates the proliferation and differentiation of human leukemia cell line K562. Physiol. Rep.6, 137966–e13815. 10.14814/phy2.13796
51
WongR. S. (2011). Apoptosis in cancer: From pathogenesis to treatment. J. Exp. Clin. Cancer Res.30, 87. 10.1186/1756-9966-30-87
52
YangH.VillaniR. M.WangH.SimpsonM. J.RobertsM. S.TangM.et al (2018). The role of cellular reactive oxygen species in cancer chemotherapy. J. Exp. Clin. Cancer Res.37, 266. 10.1186/s13046-018-0909-x
53
ZhaiK.LiskovaA.KubatkaP.BüsselbergD. (2020). Calcium entry through TRPV1: A potential target for the regulation of proliferation and apoptosis in cancerous and healthy cells. Int. J. Mol. Sci.21, 4177. 10.3390/ijms21114177
54
ZhangX.YuanD.SunQ.XuL.LeeE.LewisA. J.et al (2017). Calcium/calmodulin-dependent protein kinase regulates the PINK1/Parkin and DJ-1 pathways of mitophagy during sepsis. FASEB J.31, 4382–4395. 10.1096/fj.201601096RRR
Summary
Keywords
TRPV1, N-oleoyl-dopamine, calcium flux, chronic myeloid leukemia, oxidative stress, imatinib
Citation
Maggi F, Morelli MB, Aguzzi C, Zeppa L, Nabissi M, Polidori C, Santoni G and Amantini C (2023) Calcium influx, oxidative stress, and apoptosis induced by TRPV1 in chronic myeloid leukemia cells: Synergistic effects with imatinib. Front. Mol. Biosci. 10:1129202. doi: 10.3389/fmolb.2023.1129202
Received
21 December 2022
Accepted
31 January 2023
Published
15 February 2023
Volume
10 - 2023
Edited by
Mark Stephen Taylor, University of South Alabama, United States
Reviewed by
Vivek Krishnan, University of Nevada, Reno, United States
Ana Cipak Gasparovic, Rudjer Boskovic Institute, Croatia
Updates
Copyright
© 2023 Maggi, Morelli, Aguzzi, Zeppa, Nabissi, Polidori, Santoni and Amantini.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Consuelo Amantini, consuelo.amantini@unicam.it
This article was submitted to Cellular Biochemistry, a section of the journal Frontiers in Molecular Biosciences
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.